What are the uses of virus bacteriophage

The use of vaccines in the prophylaxis and therapy of acquired immune deficiency syndrome (AIDS)

22nd Hemophilia Symposium Hamburg 1991 pp 26-35 | Cite as

  • J. W. Mannhalter
  • M. M. Eibl

Summary

Acquired Immune Deficiency Syndrome (AIDS) has become a global health problem that is currently difficult to control. In the United States of America alone, there were more than one million HIV-infected people at the end of 1990, according to the Centers for Disease Control [1]. Although the number of new infections is falling in Europe and the United States, the number of people infected with HIV is increasing worldwide. This is mainly due to the frequency of infection in Central Africa and the spread of HIV to South America and Southeast Asia. In the USA, more than 100,000 people died from AIDS-related diseases between 1981 and 1990 [2]. The estimated increase in AIDS cases in the United States from 1991 to 1993 is between 175,000 and 250,000 and by the end of 1993 there would have been between 285,000 and 340,000 cumulative AIDS-related deaths [1].

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

literature

  1. Centers for Disease Control (1990) HIV Prevalence Estimates and AIDS Case Projections for the United States: Report Based upon a Workshop. MMWR 39: 1Google Scholar
  2. Centers for Disease Control (1991) Mortality Attributable to HIV Infection / AIDS-United States, 1981-1990. MMWR 40: 41Google Scholar
  3. Fuerst TR, Earl PL, Moss B (1987) Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol 7: 2538 PubMedGoogle Scholar
  4. Barrett N, Mitterer A, Mündt W, Eibl J, Eibl M, Gallo RC, Moss B, Dorner F (1989) Large-Scale Production and Purification of a Vaccinia Recombinant-Derived HIV-1 gpl60 and Analysis of Its Immunogenicity. Aids Research and Human Retroviruses 5: 159PubMedCrossRefGoogle Scholar
  5. Alter HJ, Eichberg JW, Masur H, Saxinger WC, Gallo R, Macher AM, Lane HC, Fauci AS (1984). Transmission of HTLV-III Infection from Human Plasma to Chimpanzees: An Animal Model for AIDS. Science 226: 549 Google Scholar
  6. Francis DP, Feorino PM, Broderson JR, McClure HM, Getchell JP, McGrath CR, Swen-son B, McDougal JS, Palmer EL, Harrison AK, Barre-Sinoussi F, Chermann JC, Mon-tagnier L, Curran JW, Cabradilla CD , Kalyanaraman VS (1984) Infection of chimpanzees with lymphadenopathy-associated virus. Lancet 11: 1276 CrossRefGoogle Scholar
  7. Lusso P, Markham PD, Ranki A, Earl P, Moss B, Dorner F, Gallo RC, Krohn KJE (1988) Cell-mediated immune response toward viral envelope and core antigens in gibbon apes (hylobates lar) chronically infected with human immunodeficiency virus -1. J Immunol 141: 2467 PubMed Google Scholar
  8. Gardner M (1991) SIV vaccines: current status. The role of the SIV-macaque model in AIDS research. Vaccine 9: 787PubMedCrossRefGoogle Scholar
  9. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobbs EK, Eichberg JW (1990) Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gpl20 but not gpl60 . Nature 345: 622PubMedCrossRefGoogle Scholar
  10. Girard M, Kieny MP, Pinter A, Barre-Sinoussi F, Nara P, Kolbe H, Kusumi K, Chaput A, Reinhart T, Muchmore E, Ronco J, Kaczorek M, Gomard E, Gluckman JC, and Fultz PN (1991) Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci 88: 542CrossRefGoogle Scholar
  11. Mannhalter JW, Barrett N, Küpcü Z, Kistner O, Wolf HM, Huber K, Eder G, Dorner F, Gallo RC, Moss B, Eibl MM (1991) Immunological Parameters Associated with Protection against Challenge with HIV-1 in rgpl60-Immunized Chimpanzees. Abstract Th.A.13. VII International Conference on AIDS. Florence June 16–21, 1991Google Scholar
  12. Mannhalter JW, Pum M, Wolf HM, Küpcü Z, Barrett N, Dorner F, Eder G, Eibl MM (1991) Immunization of Chimpanzees with the HIV-1 Glycoprotein gpl60 Induces Long-Lasting T-Cell Memory. Aids Research and Human Retroviruses 7: 485PubMedCrossRefGoogle Scholar
  13. Wintsch J, Chaignat CL, Braun DG, Jeannet M, Stalder H, Abrignani S, Montagna D, Clavijo F, Moret P, Dayer JM, Staehelin T, Doe B, Steimer KS, Dina D, Cruchaud A (1991) Safety and Immunogenicity of a Genetically Engineered Human Immunodeficiency Virus Vaccine. J Infect Dis 163: 219PubMedCrossRefGoogle Scholar
  14. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu S-L, Corey L (1991) Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337: 567PubMedCrossRefGoogle Scholar
  15. Clerici M, Tacket CO, Via CS, Lucey DR, Muluk SC, Zajac RA, Boswell RN, Berzofs-ky JA, Shearer GM (1991) Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur J Immunol 21: 1345PubMedCrossRefGoogle Scholar
  16. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, Braff EH, O’Malley P, Hawkins D, Judson FN (1982) The Prevention of Hepatitis B with Vaccine. Ann Int Med 97: 362PubMedGoogle Scholar
  17. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A (1980) Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. New Engl J Med 303: 833PubMedCrossRefGoogle Scholar
  18. Salk J (1987) Prospects for the control of AIDS by immunizing seropositive individuals. Nature 327: 473PubMedCrossRefGoogle Scholar
  19. Gibbs CJ, Jr, Peters R, Gravell M, Johnson BK, Jensen FC, Carlo DJ, Salk J (1991) Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees. Proc Natl Acad Sei USA 88: 3348CrossRefGoogle Scholar
  20. Saag MS, Hahn BH, Gibbons J, Li Y, Parks ES, Parks WP, Shaw GM (1988) Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 334: 440PubMedCrossRefGoogle Scholar
  21. Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, Brundage JF, Smith G, Johnson S, Fowler A, Wierzba T, Shafferman A, Volvovitz F, Oster C, Burke DS, and the Military Medical Consortium For Applied Retroviral Research (1991) A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gpl60 in patients with early human immunodeficiency virus infection. New Engl J Med 324: 1677PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • J. W. Mannhalter
  • M. M. Eibl
  1. 1.WienAustria